CN102238963A - 完全人源性流感m2特异性抗体 - Google Patents

完全人源性流感m2特异性抗体 Download PDF

Info

Publication number
CN102238963A
CN102238963A CN2009801487074A CN200980148707A CN102238963A CN 102238963 A CN102238963 A CN 102238963A CN 2009801487074 A CN2009801487074 A CN 2009801487074A CN 200980148707 A CN200980148707 A CN 200980148707A CN 102238963 A CN102238963 A CN 102238963A
Authority
CN
China
Prior art keywords
seq
peptide
monoclonal antibody
influenza
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801487074A
Other languages
English (en)
Chinese (zh)
Inventor
马丁·巴赫曼
莫妮卡·鲍尔
罗杰·贝利
妮可·史密茨
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of CN102238963A publication Critical patent/CN102238963A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2009801487074A 2008-12-04 2009-11-30 完全人源性流感m2特异性抗体 Pending CN102238963A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08170749 2008-12-04
EP08170749.9 2008-12-04
EP09173548 2009-10-20
EP09173548.0 2009-10-20
PCT/EP2009/066052 WO2010063675A1 (en) 2008-12-04 2009-11-30 Fully human influenza m2 specific antibodies

Publications (1)

Publication Number Publication Date
CN102238963A true CN102238963A (zh) 2011-11-09

Family

ID=42232909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801487074A Pending CN102238963A (zh) 2008-12-04 2009-11-30 完全人源性流感m2特异性抗体

Country Status (7)

Country Link
US (2) US8460670B2 (https=)
EP (1) EP2365827A1 (https=)
JP (1) JP2012510802A (https=)
CN (1) CN102238963A (https=)
AU (1) AU2009324251A1 (https=)
CA (1) CA2745598A1 (https=)
WO (1) WO2010063675A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies
EP2432803A2 (en) * 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012112489A2 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652815A (zh) * 2002-03-13 2005-08-10 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法
CN101072795A (zh) * 2004-12-06 2007-11-14 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
US20050170334A1 (en) 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US8003106B2 (en) 2002-03-13 2011-08-23 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652815A (zh) * 2002-03-13 2005-08-10 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法
CN101072795A (zh) * 2004-12-06 2007-11-14 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RONGFANGWANG: "Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein", 《ANTIVIRAL RESEARCH》 *

Also Published As

Publication number Publication date
US20110268740A1 (en) 2011-11-03
WO2010063675A1 (en) 2010-06-10
EP2365827A1 (en) 2011-09-21
US8460670B2 (en) 2013-06-11
US20130109845A1 (en) 2013-05-02
JP2012510802A (ja) 2012-05-17
CA2745598A1 (en) 2010-06-10
AU2009324251A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
US11136379B2 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
AU2012205663B2 (en) Antibodies directed against influenza
JP5683752B2 (ja) 系統グループ１及び系統グループ２のインフルエンザａ型ウイルス、並びにインフルエンザｂ型ウイルスを中和することが可能なヒト結合分子
EP2793945B1 (en) Antibodies useful in passive influenza immunization
JP6050747B2 (ja) インフルエンザ受動免疫化に有用な抗体
JP2023078352A (ja) 中和抗インフルエンザ結合分子及びその使用
US20130109845A1 (en) Fully human influenza m2 specific antibodies
CN101878228A (zh) 尼古丁特异性人单克隆抗体
HK1203410B (en) Antibodies useful in passive influenza immunization
NZ626716B2 (en) Antibodies useful in passive influenza immunization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ALATOS CO., LTD.

Free format text: FORMER OWNER: INTERCELL AG

Effective date: 20130628

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130628

Address after: No. 3, biological center, Austria, Vienna

Applicant after: Ella Toth Limited by Share Ltd

Address before: Austria Vienna

Applicant before: Intercell AG

AD01 Patent right deemed abandoned

Effective date of abandoning: 20111109

C20 Patent right or utility model deemed to be abandoned or is abandoned